Detalhe da pesquisa
1.
A comprehensive overview of metaplastic breast cancer: Features and treatments.
Cancer Sci
; 2024 May 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-38735837
2.
A real-world observation on thrombopoietic agents for patients with cancer treatment-induced thrombocytopenia in China: A multicenter, cross-sectional study.
Cancer
; 130(S8): 1524-1538, 2024 Apr 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-38515388
3.
Phase I study of the Syk inhibitor sovleplenib in relapsed or refractory mature B-cell tumors.
Haematologica
; 2024 Jan 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-38235512
4.
Ginsenoside Rg3 overcomes tamoxifen resistance through inhibiting glycolysis in breast cancer cells.
Cell Biol Int
; 48(4): 496-509, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38225685
5.
Potential diagnostic markers and therapeutic targets for periodontitis and Alzheimer's disease based on bioinformatics analysis.
J Periodontal Res
; 59(2): 366-380, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38189472
6.
Dalpiciclib plus letrozole or anastrozole versus placebo plus letrozole or anastrozole as first-line treatment in patients with hormone receptor-positive, HER2-negative advanced breast cancer (DAWNA-2): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet Oncol
; 24(6): 646-657, 2023 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-37182538
7.
Bendamustine in the treatment of patients with indolent non-Hodgkin lymphoma refractory or relapse to rituximab treatment: An open-label, single-agent, multicenter study in China.
Cancer
; 129(4): 551-559, 2023 02 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-36541221
8.
Phase I study of MSB2311, a novel pH-dependent anti-PD-L1 monoclonal antibody, treating patients with advanced solid tumors and lymphoma.
Cancer Immunol Immunother
; 72(8): 2729-2739, 2023 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-37115210
9.
Pertuzumab, trastuzumab, and docetaxel for Chinese patients with previously untreated HER2-positive locally recurrent or metastatic breast cancer (PUFFIN): final analysis of a phase III, randomized, double-blind, placebo-controlled study.
Breast Cancer Res Treat
; 197(3): 503-513, 2023 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-36463547
10.
Pamiparib in patients with locally advanced or metastatic HER2-negative breast cancer with germline BRCA mutations: a phase II study.
Breast Cancer Res Treat
; 197(3): 489-501, 2023 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-36459284
11.
Sirt3 restricts tumor initiation via promoting LONP1 deacetylation and K63 ubiquitination.
J Transl Med
; 21(1): 81, 2023 02 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-36739437
12.
Four-channel joint-polarization-frequency-multiplexing encryption meta-hologram based on dual-band polarization multiplexing meta-atoms.
Opt Express
; 31(11): 17569-17579, 2023 May 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-37381487
13.
Prognostic value of tumor necrosis based on the evaluation of frequency in invasive breast cancer.
BMC Cancer
; 23(1): 530, 2023 Jun 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-37296414
14.
Orelabrutinib for the treatment of relapsed or refractory marginal zone lymphoma: A phase 2, multicenter, open-label study.
Am J Hematol
; 98(11): 1742-1750, 2023 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-37647123
15.
Tumor-microenvironment responsive nano-carrier system for therapy of prostate cancer.
J Mater Sci Mater Med
; 34(10): 46, 2023 Sep 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-37735283
16.
Camrelizumab for relapsed or refractory classical Hodgkin lymphoma: Extended follow-up of the multicenter, single-arm, Phase 2 study.
Int J Cancer
; 150(6): 984-992, 2022 03 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-34674396
17.
Serum amyloid A 1 induces suppressive neutrophils through the Toll-like receptor 2-mediated signaling pathway to promote progression of breast cancer.
Cancer Sci
; 113(4): 1140-1153, 2022 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-35102665
18.
Dahuang Fuzi Baijiang decoction restricts progenitor to terminally exhausted T cell differentiation in colorectal cancer.
Cancer Sci
; 113(5): 1739-1751, 2022 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-35238098
19.
Safety, antitumor activity and biomarkers of sugemalimab in Chinese patients with advanced solid tumors or lymphomas: results from the first-in-human phase 1 trial.
Cancer Immunol Immunother
; 71(8): 1897-1908, 2022 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-34984540
20.
A phase Ib study of camrelizumab in combination with apatinib and fuzuloparib in patients with recurrent or metastatic triple-negative breast cancer.
BMC Med
; 20(1): 321, 2022 10 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36184642